Author:
Khosla Divya,Kapoor Rakesh,Dey Treshita,Kataria Vaishali,Singh Ranjit,Kumar Divyesh,Oinam Arun Singh,Gupta Rajesh,Rana Surinder Singh,Shah Jimil,Singh Harjeet,Irrinki Santhosh,Madan Renu
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial. Lancet Oncol. 2013;14(6):516–24.
2. Franco P, Arcadipane F, Ragona R, Mistrangelo M, Cassoni P, Rondi N, et al. Early-stage node-negative (t1–t2n0) anal cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy. Anticancer Res. 2016;36(4):1943–8.
3. Franco P, Arcadipane F, Ragona R, Mistrangelo M, Cassoni P, Rondi N, et al. Locally advanced (t3-t4 or n+) anal cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy. Anticancer Res. 2016;36(4):2027–32.
4. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal a randomized controlled trial. JAMA. 2008;299(6):1914–21.
5. Weber DC, Kurtz JM, Allal AS. The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys. 2001;50(3):675–80.